About Centogene
Centogene is a company based in Rostock (Germany) founded in 2006. Centogene has raised $28.02 million across 3 funding rounds from investors including Deutsche Private Equity, Careventures and TVM Capital Life Science. The company has 11 employees as of April 06, 2024. Centogene offers products and services including CentoGenome, CentoXome, MOx, and NGS Panels. Centogene operates in a competitive market with competitors including Invitae, Strand Life Sciences, Myriad Genetics, Genome Medical and Fulgent Genetics, among others.
- Headquarter Rostock, Germany
- Employees 11 as on 06 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Centogene N.V.
-
Annual Revenue
$52.47 M (USD)5.17as on Dec 31, 2023
-
Net Profit
-$38.41 M (USD)-14.79as on Dec 31, 2023
-
EBITDA
-$34.07 M (USD)-12.21as on Dec 31, 2023
-
Total Equity Funding
$28.02 M (USD)
in 3 rounds
-
Latest Funding Round
$16.78 M (USD), Post-IPO
Feb 01, 2022
-
Investors
Deutsche Private Equity
& 3 more
-
Employee Count
11
as on Apr 06, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Centogene
Centogene is a publicly listed company on the OTC with ticker symbol CNTGF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Centogene
Centogene offers a comprehensive portfolio of products and services, including CentoGenome, CentoXome, MOx, and NGS Panels.
Whole genome sequencing for comprehensive rare disease diagnostics
Whole exome sequencing for cost-effective patient diagnosis
Multiomics platform for deeper biological process understanding
Targeted panels for hereditary condition diagnostics
People of Centogene
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Sales and Marketing
7 people
Member Team
6 people
Data Analysis and Operations Team
6 people
Human Resources and Administration
5 people
Product Management Team
4 people
Head Team
3 people
Operations Team
2 people
Unlock access to complete
Funding Insights of Centogene
Centogene has successfully raised a total of $28.02M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $16.78 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Centogene
Centogene has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Deutsche Private Equity, Careventures and TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Careventures is focused on healthcare investments across Europe.
|
Locked | Locked | Locked | |
|
Capital is invested in life science innovations for healthcare transformation.
|
Locked | Locked | Locked |
Investor details for Centogene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Centogene
Investment portfolio details for Centogene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Centogene
Detailed financials for Centogene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Centogene Comparisons
Peer comparison for Centogene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Centogene
Centogene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invitae, Strand Life Sciences, Myriad Genetics, Genome Medical and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
Detailed competitors of Centogene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Centogene
Complete news archive for Centogene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centogene
Centogene was founded in 2006 and raised its 1st funding round 11 years after it was founded.
Centogene is headquartered in Rostock, Germany. It is registered at Rostock, Mecklenburg-vorpommern, Germany.
Centogene is a funded company, having raised a total of $28.02M across 3 funding rounds to date.
As of Apr 06, 2024, the latest employee count at Centogene is 11.
Annual revenue of Centogene is $52.47M as on Dec 31, 2023.
Founded in 2006 in Rostock, Germany, operations focus on the genetic diagnostics sector. A database called CentoMD is maintained, containing disease-causing mutations with a phenotype-genotype search tool based on the Human Phenotype Ontology. Genetic panel tests and single mutation tests are offered, alongside analytical services for neonatal screening of congenital diseases, as well as detection of breast cancer, mitochondrial disorders, infertility, stroke, vascular dementia, somatic cancer mutations, and Fabrys disease.
Centogene's top competitors include Strand Life Sciences, Fulgent Genetics and Myriad Genetics.
Centogene offers CentoGenome, CentoXome, MOx, and NGS Panels.
Yes, Centogene is publicly traded on OTC under the ticker symbol CNTGF.
Centogene has 4 investors. Key investors include Deutsche Private Equity, Careventures, TVM Capital Life Science, and Crédit Mutuel Equity.
The ticker symbol of Centogene is CNTGF on OTC.